

PHARMATHER HOLDINGS LTD.
INTERIM MANAGEMENT'S DISCUSSION AND ANALYSIS –
QUARTERLY HIGHLIGHTS

Three and Nine Months Ended February 28, 2025

(Expressed in Canadian Dollars)

Dated: April 24, 2025

INTRODUCTION

PharmaTher Inc. ("PharmaTher") was incorporated under the Business Corporations Act (Ontario) on April 1, 2020. The registered head office of the Company is 82 Richmond Street East, Toronto, Ontario M5C 1P1.

PharmaTher Holdings Ltd. (formerly Newscope Capital Corporation) ("Newscope" or the "Company") was incorporated under the Business Corporations Act (British Columbia) on March 20, 2019. The registered head office of the Company is 1055 West Georgia Street, 1500 Royal Centre, P.O. Box 11117, Vancouver B.C. V6E 4N7, Canada.

On June 10, 2020, Newscope issued 47,240,000 common shares as consideration for acquisition of all the issued and outstanding common shares in the capital of PharmaTher (the "Acquisition"). In addition, Newscope issued an aggregate of 115,000 warrants in exchange for the issued and outstanding warrants of PharmaTher. Each warrant entitles the holder thereof to acquire one common share in the capital of Newscope at an exercise price of \$0.10 for a period of 24 months from the original date of issuance. The Acquisition was accounted for as a reverse takeover ("RTO") whereby PharmaTher was identified as the acquirer for accounting purpose and the resulting consolidated financial statements are presented as a continuance of PharmaTher and the comparative figures presented in the consolidated financial statements after the RTO are those of PharmaTher. After the RTO, the combined entity of Newscope and PharmaTher is referred to as the "Company" in this Interim MD&A (defined below).

PharmaTher is a specialty pharmaceutical company focused on the development and commercialization of KETARX™ (Ketamine) to fill the global unmet medical needs for surgery, pain, mental health, neurological, and medical countermeasures indications. PharmaTher has in development novel delivery forms of ketamine via a microneedle patch and subcutaneous wearable pump to treat depression, Parkinson's disease, amyotrophic lateral sclerosis, and complex regional pain syndrome.

For investment purposes, PharmaTher owns 49% of Sairiyo Therapeutics Inc., which focuses on advancing the clinical development of an improved and patented enteric-coated orally bioavailable formulation of cepharanthine (PD-001) to treat responsive cancers, inflammatory, medical countermeasures, and infectious diseases.

The Canadian Dollar is the Company's functional and reporting currency. Unless otherwise noted, all dollar amounts are expressed in Canadian Dollars.

The following interim Management's Discussion & Analysis ("Interim MD&A") of the Company for the three and nine months ended February 28, 2025, has been prepared to provide material updates to the business operations, liquidity, and capital resources of the Company since its last annual management's discussion & analysis, being the Management's Discussion & Analysis ("Annual MD&A") for the fiscal year ended May 31, 2024. This Interim MD&A does not provide a general update to the Annual MD&A, or reflect any non-material events since the date of the Annual MD&A.

This Interim MD&A has been prepared in compliance with section 2.2.1 of Form 51-102F1, in accordance with National Instrument 51-102 – Continuous Disclosure Obligations. This discussion should be read in conjunction with the Annual MD&A and audited annual consolidated financial statements of the Company for the years ended May 31, 2024, and 2023, together with the notes thereto, and unaudited condensed interim consolidated financial statements of the Company for the three and nine months ended February 28, 2025, together with the notes thereto. Results are reported in Canadian dollars, unless otherwise noted. The Company's financial statements and the financial information contained in this Interim MD&A are prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board and interpretations of the IFRS Interpretations Committee. The unaudited condensed interim consolidated financial statements have been prepared in accordance with International Standard 34, Interim Financial

Reporting. Accordingly, information contained herein is presented as of April 24, 2025, unless otherwise indicated.

Further information about the Company and its operations can be obtained from the offices of the Company.

CAUTIONARY NOTE REGARDING FORWARD LOOKING INFORMATION

This Interim MD&A contains forward-looking information and statements ("forward-looking statements") which may include, but are not limited to, statements with respect to the future financial or operating performance of the Company. Forward-looking statements reflect the current expectations of management regarding the Company's future growth, results of operations, performance and business prospects and opportunities. Wherever possible, words such as "may", "would", "could", "will", "anticipate", "believe", "plan", "expect", "intend", "estimate" and similar expressions have been used to identify these forward-looking statements. These statements reflect management's current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the actual results, performance or events to be materially different from any future results, performance or events that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the "Risk Factors" section of this Interim MD&A. Although the Company has attempted to identify important factors that could cause actual results, performance or events to differ materially from those described in the forward-looking statements, there could be other factors unknown to management or which management believes are immaterial that could cause actual results, performance or events to differ from those anticipated, estimated or intended. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or events may vary materially from those expressed or implied by the forward-looking statements contained in this Interim MD&A. These factors should be considered carefully, and readers should not place undue reliance on the forward-looking statements. Forward-looking statements contained herein are made as of the date of this Interim MD&A and the Company assumes no responsibility to update forward looking statements, whether because of new information or otherwise, other than as may be required by applicable securities laws.

Forward-Looking Statements	Assumptions	Risk Factors
The Company's (i) development of product candidates, (ii) demonstration of such product candidates' safety and efficacy in clinical trials, and (iii) obtaining regulatory approval to commercialize these product candidates.	Financing will be available for development of new product candidates and conducting clinical studies; the actual results of the clinical trials will be favourable; development costs will not exceed the Company's expectations; the Company will be able to retain and attract skilled staff; the Company will be able to recruit suitable patients for clinical trials; all requisite regulatory and governmental approvals to commercialize the product candidates will be received on a timely basis upon terms acceptable to the Company; applicable economic conditions are favourable to the Company.	Availability of financing in the amount and time frame needed for the development and clinical trials may not be favourable; increases in costs; the Company's ability to retain and attract skilled staff; the Company's ability to recruit suitable patients for clinical trials; timely and favourable regulatory and governmental compliance, acceptances, and approvals; interest rate and exchange rate fluctuations; changes in economic conditions.
The Company's ability to obtain the substantial capital it requires to fund research and operations.	Financing will be available for the Company's research and operations and the results thereof will be favourable; debt and equity markets, exchange and interest rates and other	Changes in debt and equity markets; timing and availability of external financing on acceptable terms; increases in cost of research and operations; interest rate and

PharmaTher Holdings Ltd.
Interim Management's Discussion and Analysis – Quarterly Highlights
Three and Nine Months Ended February 28, 2025
Dated – April 24, 2025

Forward-Looking Statements	Assumptions	Risk Factors
	applicable economic conditions are favourable to the Company.	exchange rate fluctuations; adverse changes in economic conditions.
Factors affecting pre-clinical research, clinical trials and regulatory approval process of the Company's product candidates.	Actual costs of pre-clinical research, clinical and regulatory processes will be consistent with the Company's current expectations; the Company will be able to retain and attract skilled staff; the Company will be able to recruit suitable patients for clinical trials; the Company will be able to complete pre-clinical research and clinical studies on a timely basis with favourable results; all applicable regulatory and governmental approvals for product candidates will be received on a timely basis with terms acceptable to the Company; debt and equity markets, exchange and interest rates, and other applicable economic and political conditions are favourable to the Company; there will be a ready market for the product candidates.	The Company's product candidates may require time-consuming and costly pre-clinical and clinical studies and testing and regulatory approvals before commercialization; the Company's ability to retain and attract skilled staff; the Company's ability to recruit suitable patients for clinical trials; adverse changes in regulatory and governmental processes; interest rate and exchange rate fluctuations; changes in economic and political conditions; the Company will not be adversely affected by market competition.
The Company's ability to commercialize on its own or find and enter into agreements with potential partners to bring viable product candidates to commercialization.	The Company will be able to commercialize on its own or to find a suitable partner and enter into agreements to bring product candidates to market within a reasonable time frame and on favourable terms; the costs of commercializing on its own or entering into a partnership will be consistent with the Company's expectations; partners will provide necessary financing and expertise to bring product candidates to market successfully and profitably.	The Company will not be able to commercialize on its own or find a partner and/or enter into agreements within a reasonable time frame; if the Company enters into agreements, these agreements may not be on favourable terms to the Company; costs of entering into agreements may be excessive; potential partners will not have the necessary financing or expertise to bring product candidates to market successfully or profitably.
The Company's ability to obtain and protect the Company's intellectual property rights and not infringe on the intellectual property rights of others.	Patents and other intellectual property rights will be obtained for viable product candidates; patents and other intellectual property rights obtained will not infringe on others.	The Company will not be able to obtain appropriate patents and other intellectual property rights for viable product candidates; patents and other intellectual property rights obtained will be contested by third parties; no proof that acquiring a patent will make the product more competitive.
The Company's ability to source markets which have demand for its products and successfully supply those markets in order to generate sales.	The anticipated markets for the Company's potential products and technologies will continue to exist and expand; the Company's products will be commercially viable, and it will successfully compete with other	The anticipated market for the Company's potential products and technologies will not continue to exist and expand for a variety of reasons, including competition from other products and the degree of

PharmaTher Holdings Ltd.
Interim Management's Discussion and Analysis – Quarterly Highlights
Three and Nine Months Ended February 28, 2025
Dated – April 24, 2025

Forward-Looking Statements	Assumptions	Risk Factors
	research teams who are also examining potential products.	commercial viability of the potential product.
Future actions with respect to and potential impacts of pending claims.	The Company will be able to settle or otherwise obtain disposition of claims against it on favourable terms.	The Company may will not be able to settle pending claims on favourable terms; claims may be adjudicated in a manner that is not favourable to the Company.

Inherent in forward-looking statements are risks, uncertainties, and other factors beyond the Company's ability to predict or control. Please also make reference to those risk factors referenced in the "Risk Factors" section below. Inherent in forward-looking statements are risks, uncertainties, and other factors beyond the Company's ability to predict or control. Please also refer to those risk factors referenced in the "Risk Factors" section below. Readers are cautioned that the above chart does not contain an exhaustive list of the factors or assumptions that may affect the forward-looking statements, and that the assumptions underlying such statements may prove to be incorrect. Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this Interim MD&A.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance, or achievements to be materially different from any of its future results, performance or achievements expressed or implied by forward-looking statements. All forward-looking statements herein are qualified by this cautionary statement. Accordingly, readers should not place undue reliance on forward-looking statements. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements whether as a result of new information or future events or otherwise, except as may be required by law. If the Company does update one or more forward-looking statements, no inference should be drawn that it will make additional updates with respect to those or other forward-looking statements, unless required by law.

BUSINESS OVERVIEW

PharmaTher is a specialty pharmaceutical company focused on the development and commercialization of KETARX™ (Ketamine) to fill the global unmet medical needs for surgery, pain, mental health, neurological, and medical countermeasures indications. PharmaTher has in development novel delivery forms of ketamine via a microneedle patch and subcutaneous wearable pump to treat depression, Parkinson's disease, amyotrophic lateral sclerosis, and complex regional pain syndrome. The Company aims to leverage the U.S. Food and Drug Administration ("FDA") regulatory incentives for expedited approvals, such as the FDA 505(b)(2) regulatory pathway, orphan drug, and fast track designations. PharmaTher's patent portfolio includes granted and provisional patents on method of uses of KETARX™ and drug delivery systems. In addition, the Company actively seeks licensing, acquisition or partnership opportunities from industry and academia.

For investment purposes, PharmaTher owns 49% of Sairiyo Therapeutics Inc., which focuses on advancing the clinical development of an improved and patented enteric-coated orally bioavailable formulation of cepharanthine (PD-001) to treat responsive cancers, inflammatory, medical countermeasures, and infectious diseases.

CORPORATE HIGHLIGHTS

On August 18, 2024, the Company announced that Sairiyo a company that is forty-nine percent (49%) owned by PharmaTher and fifty-one percent (51%) owned by PharmaDrug Inc., has received approval by the Australian Human Research Ethics Committee to initiate a first-in-human Phase 1 clinical study (the "Study") investigating a patented reformulated enteric coated version of oral cepharanthine ("PD-001") as a potential treatment for Medical

Countermeasures and cancer. PD-001 was previously awarded a \$3.4 million contract from the Defense Threat Reduction Agency (DTRA) for the Ebola virus.

On August 21, 2024, the Company announced that Sairoyo a company that is forty-nine percent (49%) owned by PharmaTher and fifty-one percent (51%) owned by PharmaDrug Inc., announced today that an independent screening of drugs for monkeypox ("Mpox") highlighted cepharanthine's potential to bind to the virus's proteins. The letter to the editor titled, "Highly accurate protein structure prediction and drug screen of monkeypox virus proteome", is non peer reviewed and published in Journal of Infection and can be found at: [https://www.journalofinfection.com/article/S0163-4453\(22\)00470-4/fulltext](https://www.journalofinfection.com/article/S0163-4453(22)00470-4/fulltext).

On September 4, 2024, the Company announced an update for its New Drug Application for Ketamine from the FDA with an assigned a Generic Drug User Fee Amendments of 2022 ("GDUFA") goal date of October 29, 2024. On September 3, 2024, the FDA communicated with the Company that the review is ongoing and no additional information is needed but is subject to change. The Company will continue to provide updates as they occur.

On October 23, 2024, the Company announced that the FDA has issued a complete response letter (CRL), dated October 22, 2024, for the ketamine Abbreviated New Drug Application, which was assigned a GDUFA goal date of October 29, 2024.

The deficiencies cited in the CRL are classified as MINOR. The FDA requested new and updated information and clarifications related to drug substance, drug product, manufacturing, and microbiology. The FDA did not express concern about the stability of the ketamine submission batches, which achieved 18 months of stability without issue, and no new preclinical and clinical studies were requested.

As noted by the FDA in the CRL, the resubmission to this CRL will be considered to represent a MINOR AMENDMENT, given that the deficiencies have been classified as MINOR. The Company will be working with its third-party manufacturing partner to resolve these deficiencies and respond to the FDA in a timely fashion. The Company will provide a timeline for responding to the FDA as soon as possible and continue to provide updates as they occur.

On February 12, 2025, the Company announced that the Company was on track to resubmit information to the FDA by end-February 2025. This resubmission, which addresses the deficiencies classified as MINOR in the complete response letter ("CRL") provided by the FDA dated October 22, 2024, is a significant step towards obtaining FDA approval. The Company expects to receive a new approval date for a Q2-2025 FDA approval.

On March 3, 2025 the Company announced that the Company has provided its resubmission to the complete response amendment for its FDA new drug application for Ketamine, which addresses the deficiencies classified as MINOR in the CRL provided by the FDA dated October 22, 2024.

On March 11, 2025, the Company announce that the Company has received an Amendment Acknowledgement Letter ("AAL") from the FDA for its New Drug Application for Ketamine. In the AAL, the FDA determined this is a minor amendment, meets the criteria for priority review, and assigned an approval goal date of June 4, 2025.

RESEARCH

Details of the research expenditures for the periods presented, are provided below:

PharmaTher Holdings Ltd.
Interim Management's Discussion and Analysis – Quarterly Highlights
Three and Nine Months Ended February 28, 2025
Dated – April 24, 2025

Name	Three months ended February 28, 2025	Three months ended February 29, 2024	Nine months ended February 28, 2025	Nine months ended February 29, 2024
Ketamine	154,484	137,555	287,348	1,701,952
Microneedle	nil	34,247	45,000	104,537
Other	nil	28,369	(84)	141,436
Total	154,484	200,171	332,264	1,947,925

PharmaTher is a specialty pharmaceutical company focused on the development and commercialization of KETARX™ (Ketamine) to fill the global unmet medical needs for surgery, pain, mental health, neurological, and medical countermeasures indications. PharmaTher has in development novel delivery forms of ketamine via a microneedle patch and subcutaneous wearable pump to treat depression, Parkinson's disease, amyotrophic lateral sclerosis, and complex regional pain syndrome. For investment purposes, PharmaTher owns 49% of Sairyo Therapeutics Inc., which focuses on advancing the clinical development of an improved and patented enteric-coated orally bioavailable formulation of cepharanthine (PD-001) to treat responsive cancers, inflammatory, medical countermeasures, and infectious diseases.

Ketamine

PharmaTher is developing KETARX™ (Ketamine) for rare or near-rare disorders, such as Parkinson's disease, amyotrophic lateral sclerosis, complex regional pain syndrome, as well as larger unmet needs in depression, surgical and pain management. PharmaTher's ketamine product has been granted an FDA approval goal date of June 2025 ([see press release](#)).

Ketamine is a rapid-acting, nonbarbiturate general anesthetic approved by the FDA in 1970 and is clinically used for analgesia, sedation, and anesthetic induction. Ketamine is a generic drug classified by the Drug Enforcement Agency ("DEA") as a Schedule III controlled substance. Published studies have demonstrated ketamine's potential in major depressive disorder, bipolar depression, depression with suicidal ideation, post-traumatic stress disorder, drug addiction, Parkinson's disease, and pain management.

Solving the Ketamine shortage problem in the U.S.

PharmaTher is committed to solving the Ketamine shortage problem in the United States of America and adhering to the FDA's strict manufacturing guidelines. Ketamine has been on the FDA's drug shortage list since February 2018, which is believed to have encouraged the widespread availability of compounded Ketamine products. On October 10, 2023, the FDA published a compounding risk alert describing the potential risks associated with compounded Ketamine products for psychiatric disorders. The outcome with resolving Ketamine's drug shortage issue would be similar to the recent news of Wegovy and Ozempic being removed from the FDA drug shortage list and compounders have a 60-to-90 day grace period to stop supplying them (see FDA letter).

With ketamine removed from the FDA drug shortage list, the FDA is expected to restrict compound pharmacies from supplying it, opening the door for PharmaTher to fill the demand gap in the U.S. market.

Unlocking the pharmaceutical potential of Ketamine

With pending FDA approval for Ketamine on the horizon, the Company remains focused on its mission to be a leading innovator and provider of Ketamine to treat unmet medical needs.

It is well-known that Ketamine is an essential medicine used for anesthesia and analgesia (pain relief), listed on the WHO Essential Medicines List, and used as a sedative and painkiller in hospital settings. Outside of the FDA and Health Canada approved indications, Ketamine is also being administered in hospitals and clinics to treat various pain, neurological, and mental health disorders. A published peer-reviewed study on the real-world effectiveness of Ketamine intravenous therapy demonstrated significant patient improvement for depression, anxiety and suicidal ideation.

The potential of Ketamine to significantly impact patient lives is immense. PharmaTher, with its innovative approaches and commitment to patient care, is poised to play a pivotal role in making Ketamine available to millions of people globally.

Ketamine for anesthesia and procedural sedation

The first indication for KETARX™ (Ketamine) is aimed as an anaesthetic agent for diagnostic and surgical procedures. The Company expects commercialize ketamine to hospitals, clinics, and government, and aims to form partnerships with research labs, ketamine clinics and pharmaceutical companies that are: seeking a secure supply of cGMP ketamine and ketamine products for current portfolios; exploring alternative dose forms for multiple existing indications; and requiring support to develop and eventually commercialize specific ketamine products for new indications. In addition, the Company will enter the market with KETARX™ targeting ketamine's FDA approved label for anesthesia and procedural sedation. The Company has filed a Priority Original Abbreviated New Drug Application and has been granted an FDA approval goal date of June 4, 2025. PharmaTher will also seek regulatory approvals for international markets.

Ketamine for Parkinson's disease

Parkinson's disease is a debilitating disorder that affects over 1 million people in the U.S. and more than 7 million people worldwide. There is currently no cure for Parkinson's disease, although some drug combinations are used to treat the disease symptoms. Levodopa is the gold standard for Parkinson's disease treatment but features significant drawbacks, including the major side effect of dyskinesia and a loss of effectiveness over time. Approximately 50% of patients with PD will develop Levodopa-induced dyskinesia ("LID") 4-5 years after the initiation of levodopa therapy, and this number rises to 80% after 10-12 years of levodopa treatment. LID may interfere with motor function, cause or aggravate pain and is known to worsen the quality of life significantly. Individuals with Parkinson's disease may experience a host of non-motor symptoms such as autonomic dysfunction, psychiatric (depression), cognitive and sensory symptoms (pain). Therefore, there is an urgent need for alternative treatments and has been identified by the regulatory authorities, patient advocacy groups such as Michael J. Fox Foundation, and key opinion leaders as a substantial unmet medical need.

PharmaTher has entered into an exclusive license agreement with the University of Arizona for the development and commercialization of ketamine in the treatment of Parkinson's disease. Ketamine is an FDA-approved drug with a known safety profile. Prior clinical reports suggest that low-dose ketamine infusions are well tolerated and can improve pain and depression, both often comorbidities in Parkinson's disease patients. Inventors Dr. Scott Sherman and Dr. Torsten Falk, both associate professors at The University of Arizona College of Medicine – Tucson, have patented the results from preclinical data and five case studies in Parkinson's disease patients showing that low-dose sub-anesthetic ketamine infusion indicates tolerability, safety, and the potential of long-term therapeutic benefit to reduce Levodopa-induced dyskinesia, improve on time, and reduce depression.¹⁻⁵

The FDA has approved the Company's Investigational New Drug application to proceed with a Phase 2 clinical trial to evaluate the safety, efficacy and pharmacokinetics of ketamine in the treatment of LID-PD. PharmaTher recently announced the presentation of a Phase 1/2 clinical study involving ketamine in the treatment of LID-PD. The data from this study demonstrated ketamine's safety and tolerability with clinically meaningful efficacy that supports further investigation in a proposed Phase 3 clinical study as a potential new treatment for LID-PD and the Company would seek FDA approval via the 505(b)(2) regulatory pathway. The Company is evaluating the proposed clinical development plan, which includes the Phase 3 clinical study, for FDA approval.

Ketamine for Amyotrophic Lateral Sclerosis

ALS is a progressive neuromuscular disease with a life expectancy of only two to six years after diagnosis. Currently, there is no known cure for ALS. ALS affects approximately 50,000 people in the U.S. and Europe, with over 5,000 new cases diagnosed annually. As ALS advances, upper and lower motor neurons die, causing the brain to lose its ability to control muscle movement. ALS patients experience progressive loss of voluntary muscle action as an effect of the disease, resulting in the inability to speak, eat, move and, eventually, breathe. The FDA approved only three pharmaceuticals for the treatment of ALS: riluzole, edaravone, and Nuedexta (dextromethorphan HBr and quinidine sulfate). These drugs are effective against disease mechanisms of ALS but fail to have measurable effects on attenuating disease progression or improve survival. Therefore, there is an imperative need for new pharmacological therapies that can stop or slow the muscle decline associated with ALS progression and extend the life expectancy of the ALS patient.

PharmaTher entered into an exclusive license agreement with The University of Kansas to develop and commercialize the intellectual property of ketamine to treat ALS. Ketamine has the potential to effectively increase the life expectancy of those with ALS at any stage and slow the progressive loss of muscle associated with poor outcomes of the disease. The University of Kansas Medical Center researchers and inventors of the potential use of ketamine to treat ALS, Dr. Richard J. Barohn, M.D., John A. Stanford, Ph.D., and Dr. Matthew Macaluso, D.O., have made the promising discovery that ketamine can be administered as an effective treatment for ALS. Patented preclinical research has shown that the administration of ketamine preserves muscle function in advancing ALS and increases life expectancy when given in the early stages of muscle decline. Ketamine works by blocking the action of the ionotropic glutamate receptor, the NMDA receptor. Unlike other inhibitors of NMDA receptor function, such as riluzole, ketamine dampens NMDA receptor-related glutamate excitotoxicity indirectly. Further, ketamine can lower

1. UA Clinical Trial to Repurpose Ketamine for Parkinson's Patients.
2. US20190060254A1— Compositions and methods for treating motor disorders.
3. Bartlett, et al, 2020. Preclinical evidence in support of repurposing sub-anesthetic ketamine as a treatment for L-DOPA-induced dyskinesia. *Experimental Neurology*. Volume 333.
4. Bartlett, M.J., Joseph, R.M., LePoidevin, L.M., Parent, K.L., Laude, N.D., Lazarus, L.B., Heien, M.L., Estevez, M., Sherman, S.J., Falk, T., 2016. Long-term effect of sub-anesthetic ketamine in reducing L-DOPA-induced dyskinesias in a preclinical model.
5. Sherman, S.J., Estevez, M., Magill, A.B., Falk, T., 2016. Case reports showing a long-term effect of subanesthetic ketamine infusion in reducing L-DOPA-induced dyskinesias. *Case Rep. Neurol.* 8, 53–58.

D-serine concentrations intracellularly and also partially activates dopamine receptors. Collectively, these mechanisms of ketamine contribute in part to the drug's neuroprotective effects, which may extend to the motor neurons targeted in ALS.

The FDA has accepted an investigator-initiated investigational new drug application to proceed with a Phase 2 clinical trial evaluating ketamine in the treatment of ALS. Assuming the study is positive, the Company will request a meeting with the FDA to discuss its plan and obtain an agreement to move to a Phase 3 clinical study and accelerated marketing approval. The Company will seek regulatory approval under the FDA 505(b)(2) regulatory pathway. The Company has decided to pause allocating funds for this program for the remainder of 2025 to conserve capital for the potential launch of KETARX™ in 2025 in the U.S. The Company will evaluate this program quarterly to determine a potential rationale to reviving it or partnering with potential pharmaceutical partners.

Ketamine Microneedle Patch

The Company is developing KETARX™ (Ketamine) microneedle patch, for mental health, neurological and pain disorders. KETARX™ microneedle patch aims to empower patients to dose their medication remotely, safely and conveniently rather than being under supervision by a healthcare provider at a certified medical office. KETARX™ microneedle patch has the potential to incorporate anti-tampering and anti-abuse features and the delivery format of the product that would parallel the approach used for the tamper-resistant transdermal fentanyl patch. In a research project with The Queen's University of Belfast, led by Professor Ryan Donnelly, the Company has successfully completed the evaluation of a patented hydrogel-forming microneedle patch to deliver KETARX™. This de-risking milestone supports the Company's expansion in finalizing IND-enabling studies and the clinical manufacturing scale up with LTS Lohmann. The Company has decided to pause allocating funds for its ketamine microneedle patch program for the remainder of 2025 to conserve capital for the potential launch of KETARX™ in 2025 in the U.S. The Company will evaluate this program quarterly to determine a potential rationale to reviving it or partnering with potential pharmaceutical partners.

In addition to ketamine, the Company's microneedle patch technology solution can also be applied to psychedelics (i.e., psilocybin, DMT, LSD and MDMA, etc) and infectious diseases. The Company seeks to develop and partner these programs with life sciences companies. Such partnerships may offer an additional investment and revenue stream through equity, licensing, milestones, royalties and development fees.

Ketamine Wearable Pump

PharmaTher aims to commercialize KETARX™ Wearable Pump (subcutaneous ketamine) for the maintenance of general anesthesia for diagnostic and surgical procedures, and pain indications. The Company believes that subcutaneous infusion of ketamine via the on-body pump device has several advantages for ketamine procedural sedation, including decreased requirement for skilled personnel for its administration, reduction in pain and irritation associated with administration, and a reduced risk of systemic infection and other complications seen with IV administration. The Company has partnered with CC Biotechnology Corporation, a leader in the design and manufacturing of wearable, pen and auto injectors, for the development of the KETARX™ Wearable Pump solution for mental health, neurological and pain disorders. The Company believes that in the natural evolution of chronic disease management, a logical progression from IV and IM to wearable injection systems could increase the convenience, compliance, and dose flexibility for both caregivers and patients. The Company has decided to pause allocating funds for its on-body pump program for the remainder of 2025 to conserve capital for the potential launch

of KETARX™ in 2025 in the U.S. The Company will evaluate this program quarterly to determine a potential rationale to reviving it or partnering with potential pharmaceutical partners.

FINANCIAL RESULTS

The Company reported a net loss of \$369,484 for the three months ended February 28, 2025, which is comprised of loss from investment in Sairiyo of \$23,122, research of \$154,484, consulting fee of \$115,000, general, and administrative of \$58,473, shareholder information and filing fees of \$7,411 and professional fees of \$22,089. The Company is maintaining reporting issuer status while moving forward in its research initiatives as outlined under "Research and Development" above.

The Company reported a net loss of \$362,762 for the three months ended February 29, 2024, which is comprised of unrealized gain on investment of \$26,667, loss from investment in Sairiyo of \$6,311, research of \$200,171, consulting fee of \$130,143, general, and administrative of \$69,242, shareholder information and filing fees of \$7,457 and professional fees of \$14,644 offset by interest income \$38,539. The Company is maintaining reporting issuer status while moving forward in its research initiatives as outlined under "Research and Development" above.

The Company reported a net loss of \$1,117,320 for the nine months ended February 28, 2025, which is comprised of unrealized loss on investment of \$100,000, loss from investment in Sairiyo of \$39,308, research of \$332,264, consulting fee of \$360,457, general, and administrative of \$205,320, shareholder information and filing fees of \$36,261 and professional fees of \$98,585. The Company is maintaining reporting issuer status while moving forward in its research initiatives as outlined under "Research and Development" above.

The Company reported a net loss of \$2,754,741 for the nine months ended February 29, 2024, which is comprised of unrealized loss on investment of \$166,666, loss from investment in Sairiyo of \$54,704, research of \$1,947,925, consulting fee of \$408,440, general, and administrative of \$222,792, shareholder information and filing fees of \$32,973 and professional fees of \$78,651 offset by interest income \$157,410. The Company is maintaining reporting issuer status while moving forward in its research initiatives as outlined under "Research and Development" above.

LIQUIDITY AND CAPITAL RESOURCES

The Company's approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities when due. The Company's liquidity and operating results may be adversely affected if the Company's access to the capital market is hindered, whether because of a downturn in stock market conditions generally or because of conditions specific to the Company. The Company regularly evaluates its cash position to ensure preservation and security of capital as well as maintenance of liquidity. As the Company does not presently generate revenue to cover its costs, managing liquidity risk is dependent upon the ability to secure additional financing. The recoverability of the carrying value of the assets and the Company's continued existence is dependent upon the achievement of profitable operations, or the ability of the Company to raise alternative financing, as necessary. While management and the Board have been successful in raising the necessary capital, it cannot provide assurance that it will be able to execute on its business strategy or be successful in future financing activities.

As of February 28, 2025, the Company had a cash balance of \$1,225,242 to settle current liabilities of \$300,266. The Company has deficit of \$11,945,261 as of February 28, 2025.

The table below outlines the comparison of the Company's actual and planned uses of working capital from June 1, 2024, to May 31, 2025:

PharmaTher Holdings Ltd.
Interim Management's Discussion and Analysis – Quarterly Highlights
Three and Nine Months Ended February 28, 2025
Dated – April 24, 2025

Use of Capital	Estimated Cost	Spent to February 28, 2025 (approx.)	Remaining Funds to Spend or (excess)
General and administrative ⁽¹⁾	\$600,000	\$623,000	(\$23,000)
Sales and marketing	\$100,000	\$62,000	\$38,000
Research and development ⁽²⁾	\$250,000	\$332,000	(\$82,000)
Total	\$950,000	\$1,017,000	(\$67,000)

Notes:

- (1) This figure is for a forecasted period from June 1, 2024, to May 31, 2025, and is comprised of consulting fees in the amount of approximately \$400,000, professionals' fees in the amount of approximately \$100,000, transfer agent and regulatory fees in the amount of approximately \$50,000, and insurance and office expenses in the amount of approximately \$50,000.
- (2) This figure is for a forecasted period from June 1, 2024, to May 31, 2025, and is comprised of anticipated costs of \$150,000 in connection with the development and production of KETARX™ for regulatory submissions and commercialization, and anticipated costs of \$100,000 for general research and development.

Unallocated funds will be deposited in the Company's bank account and added to the working capital of the Company. Based on the Company's cash flow requirements, management will determine the appropriate level of liquidity required for operations and will draw down such funds as necessary.

There may be circumstances, where for business reasons, a reallocation of funds may be necessary for the Company to achieve its stated business objectives.

The Company had negative cash flow from operating activities for the nine months ended February 28, 2025. The Company cannot guarantee it will have a cash flow positive status from operating activities in future periods. As a result, the Company continues to rely on the issuance of securities or other sources of financing to generate sufficient funds to fund its working capital requirements and for corporate expenditures. The Company may continue to have negative cash flow from operating activities until sufficient levels of sales are achieved. To the extent that the Company has negative cash flow from operating activities in future periods, the Company may need to use a portion of proceeds from any offering to fund such negative cash flow.

TRENDS AND ECONOMIC CONDITIONS

There can be no assurance that additional funding will be available to the Company, which could delay some of the Company's planned or proposed business activities. In addition, external risks like a trade dispute with the U.S. could put significant strain on Canada's broader economy. Tit-for-tat import tariffs are generally inflationary and would raise costs. Management, in conjunction with the Board of Directors, will continue to monitor these developments and their effect on the Company's business.

Strong equity markets are favourable conditions for completing a public merger, financing, or acquisition transactions. Management regularly monitors economic conditions and estimates their impact on the Company's operations and incorporates these estimates in both short-term operating and longer-term strategic decisions. Inflation increases major operating expenses like service provider costs such as accounting, costs of being a reporting issuer, legal and audit costs. The Company works to counteract rising expenses. Despite the best

PharmaTher Holdings Ltd.
Interim Management's Discussion and Analysis – Quarterly Highlights
Three and Nine Months Ended February 28, 2025
Dated – April 24, 2025

efforts to control costs where possible, inflationary pressures nonetheless introduce added financial burdens on the Company.

Apart from these and the risk factors noted under the heading "Risk Factors" and "Cautionary Note Regarding Forward-Looking Information", management is not aware of any other trends, commitments, events or uncertainties that would have a material effect on the Company's business, financial condition or results of operations.

COMMITMENTS

The Company has entered into an exclusive patent license agreement with the Arizona Board of Regents on behalf of the University of Arizona, whereby certain milestone payments and royalties are payable upon the achievement of certain events. The Company will record these amounts as the events occur.

The Company has entered into an exclusive license agreement with The University of Kansas, whereby certain milestone payments and royalties are payable upon the achievement of certain events. The Company will record these amounts as the events occur.

RELATED PARTY TRANSACTIONS

(a) Related party balances and transactions

Related parties include the directors of the Company, close family members and enterprises which are controlled by these individuals as well as persons performing similar functions.

Name	Three months ended February 28, 2025	Three months ended February 29, 2024	Nine months ended February 28, 2025	Nine months Ended February 29, 2024
Fabio Chianelli (i)	90,000	90,000	270,000	270,000
Marrelli Support Services Inc. ("MSSI") (ii)	10,240	10,240	37,479	37,414
DSA Corporate Services LP ("DSA") (iii)	4,810	2,104	20,225	18,515
Larnic Inc. (iv)	15,000	45,000	105,000	135,000
Marrelli Trust Company Limited ("Marrelli Trust") (v)	1,522	1,290	5,290	4,932
Total	121,572	148,634	437,994	465,861

(i) Fees are related to services of Fabio Chianelli to act as the Chief Executive Officer ("CEO") of the Company. Fabio Chianelli is the owner of Fabiotech Inc. As at February 28, 2025, \$nil (May 31, 2024 - \$nil) was owed to the CEO.

(ii) Fees are related to services of Carmelo Marrelli to act as the Chief Financial Officer ("CFO") of the Company. Carmelo Marrelli is the Managing Director of MSSI. Services were incurred for bookkeeping, accounting and CFO services. As at February 28, 2025, MSSI was owed \$2,318 (May 31, 2024 - \$2,318) and this amount was included in accounts payable and accrued liabilities. This amount is unsecured and non-interest bearing.

(iii) The CFO of the Company is an officer of DSA and the Corporate Secretary of the Company is an employee of DSA. Fees are related to corporate secretarial and filing services provided by DSA. As at February 28, 2025, DSA was owed \$4,277 (May 31, 2024 - \$3,955) and this amount was included in accounts payable and accrued liabilities. This amount is unsecured and non-interest bearing.

(iv) During the three and nine months ended February 28, 2025, the Company incurred consulting fees of \$15,000 and \$105,000, respectively (three and nine months ended February 29, 2024 - \$45,000 and \$135,000, respectively) to a company controlled by the spouse of the CEO and the consulting fees have been included in research expenses, which services supported aspects of the product and clinical development, regulatory and market research of the Company's product pipeline. As at February 28, 2025, the company controlled by the spouse of the CEO was owed \$nil (May 31, 2024 - \$nil).

(v) The CFO of the Company is a director of Marrelli Trust. Marrelli Trust provided stock transfer services to the Company. As at February 28, 2025, Marrelli Trust was owed \$1,256 (May 31, 2024 - \$463) and this amount was included in accounts payable and accrued liabilities. This amount is unsecured and non-interest bearing.

(vi) During the year ended May 31, 2021, one of the officers of the Company paid research and development expenses in the amount of \$2,608 on behalf of the Company. As at February 28, 2025, the Company owed \$2,102 (May 31, 2024 - \$2,046) to the officer.

(b) Remuneration of directors and key management

In accordance with IAS 24, key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Company directly or indirectly, including any directors (executive and non-executive) of the Company. During the three and nine months ended February 28, 2025, and February 29, 2024, the Company incurred no remuneration of management with the exception of the consulting fees paid to the CEO and CFO as outlined above.

(c) Major shareholders

To the knowledge of the directors and senior officers of the Company, as of February 28, 2025, no person or corporation beneficially owns or exercises control over common shares of the Company carrying more than 10% of the voting rights attached to all common shares of the Company other than Mr. Fabio Chianelli who owns 17.53% of the Company. The holding can change at any time at the discretion of the owners.

None of the Company's major shareholders have different voting rights compared to holders of the Company's common shares.

The Company is not aware of any arrangements the operation of which may at a subsequent date result in a change in control of the Company. To the knowledge of the Company, it is not directly or indirectly owned or controlled by another corporation, by any government or by any natural or legal person severally or jointly.

RISK FACTORS

An investment in the securities of the Company is highly speculative and involves numerous and significant risks. Such investment should be undertaken only by investors whose financial resources are sufficient to enable

them to assume these risks and who have no need for immediate liquidity in their investment. Prospective investors should carefully consider the risk factors that have affected, and which in the future are reasonably expected to affect, the Company and its financial position. Please refer to the section entitled "Risk Factors " in the Company's Annual MD&A for the year ended May 31, 2024.